Background Differences in adherence may represent drug properties (eg dosing interval) or
patient experiences while on treatment. Adherence to direct oral anticoagulants (DOACs) in …

Background: Real-world evidence from published observational studies of adherence to
Novel Oral Anticoagulants (NOACs) medications and associated clinical outcome events in …

Background Despite simpler regimens than vitamin K antagonists (VKAs) for stroke
prevention in atrial fibrillation (AF), adherence (taking drugs as prescribed) and persistence …

Background A high degree of adherence to direct oral anticoagulants is essential for
reducing the risk of ischaemic stroke and systemic embolism in patients with atrial fibrillation …

BACKGROUND: Direct oral anticoagulants (DOACs) are widely used for the prevention of
stroke in nonvalvular atrial fibrillation (NVAF); however, real-world primary nonadherence …

Objectives: To estimate the real-world (RW) impact of adherence to once-daily (QD:
rivaroxaban and edoxaban) and twice-daily (BID: apixaban and dabigatran) non-vitamin K …

Background For most patients with newly diagnosed atrial fibrillation (AF), direct oral
anticoagulants (DOACs) are preferred over vitamin K antagonists. However, there is concern …

Atrial fibrillation (AF) is a growing public health concern and remains an independent risk
factor for ischemic stroke. Warfarin, a commonly used oral anticoagulant, is associated with …

BACKGROUND: Primary nonadherence (not filling a first prescription) is an important yet
unstudied aspect of adherence to oral anticoagulant (OAC) therapy. OBJECTIVE: To …

Background Direct oral anticoagulants (DOACs) are widely used in patients with nonvalvular
atrial fibrillation for stroke prevention. However, long‐term adherence to DOACs and clinical …